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Abstract
Cytomegalovirus (CMV) infection is endemic worldwide but its seroprevalence varies widely.
The goal of this study was to estimate the age-specific seroprevalence of CMV infection in
Belgium based on two cross-sectional serological datasets from 2002 and 2006. The seropreva-
lence was estimated relying on diagnostic test results based on cut-off values pre-specified by
the manufacturers of the tests as well as relying on mixture models applied to continuous
pathogen-specific immunoglobulin G antibody titre concentrations. The age-specific sero-
prevalence of hepatitis A virus (HAV), based on three Belgian cross-sectional serological
datasets from 1993, 2002 and 2006, was used as a comparator since individuals acquire life-
long immunity upon recovery, implying an increasing seroprevalence with age. The age group
weighted overall CMV seroprevalence derived from the mixture model was 32% (95% confi-
dence interval (CI) 31–34%) in 2002 and 31% (95% CI 30–32%) in 2006. We demonstrated
that CMV epidemiology differs from the immunizing infection HAV. This was the first large-
scale study of CMV and HAV serial datasets in Belgium, estimating seroprevalence specified
by age and birth cohort.
Introduction
Cytomegalovirus (CMV) is a herpes virus that spreads mainly via close contacts through
infected bodily fluids such as urine, blood, saliva or genital secretions [1]. The CMV sero-
prevalence varies globally and ranges approximately between 40% and 100% in adolescents
and adults [2]. In immunocompetent children and adults, CMV infection remains usually
asymptomatic, although it can cause mononucleosis-like symptoms and can occasionally
lead to severe disease. By contrast, in immunocompromised patients, CMV infection is likely
to cause significant morbidity and mortality and in pregnant women it may infect the unborn
child through the placenta [3]. Such a congenital CMV (cCMV) infection is usually asymp-
tomatic but may also lead to lifelong disabilities and even foetal or neonatal death [4].
Although several CMV vaccine candidates are under development, there is currently no
licensed CMV vaccine available on the market [5].
Hepatitis A virus (HAV) is mainly transmitted through the faecal–oral route by ingestion of
contaminated water or food, although close contact person-to-person transmission may also
occur via this route, as well as via blood. Age-dependent HAV seroprevalence varies geograph-
ically and improvements in socio-economic, hygienic and food-safety conditions and to a
lesser extent, active and passive immunisation activities, reduced the HAV force of infection,
and thus lowered the overall seroprevalence over time [6, 7, 8]. HAV infection is usually symp-
tomatic in adults and asymptomatic in young children (<5 years of age). Symptomatic hepa-
titis A infection may exceptionally lead to fulminant hepatitis and death. These severe
manifestations are also more likely in adulthood than in childhood. The World Health
Organization (WHO) emphasises that in countries with low and very low hepatitis A
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endemicity, vaccination should be targeted primarily to the
groups at increased risk of hepatitis A [9]. Currently available
inactivated HAV vaccines have been shown to provide long-term
protection, with antibody persistence for 20 years after vaccin-
ation in more than 97% of vaccine recipients. Mathematical mod-
els predict 30 years of antibody persistence in over 95% of vaccine
recipients [10, 11].
After primary infection with CMV or HAV, individuals
acquire immunoglobulin G (IgG) antibodies against these patho-
gens. For HAV, IgG can also be vaccine-induced. Since the accu-
mulated exposure time increases with age and the presence of IgG
antibodies indicates past infection, the seroprevalence of IgG is
expected to be monotonically increasing with age, provided that
there is lifelong humoral immunity, time equilibrium at the dis-
ease (endemic equilibrium) and population level (demographic
equilibrium), and that mortality attributable to infection can be
ignored [12, 13].
Since HAV IgG antibodies are a marker of humoral immunity
and assumed to be persisting through life [7, 14], HAV infections
can be referred to as immunizing and conferring lifelong humoral
immunity. In contrast, it was demonstrated that reactivation may
contribute significantly to the transmission dynamics of CMV
[15]. Primary infection is followed by latent infection that can reacti-
vate, but also reinfection with a different CMV strain can occur,
independent of anti-CMV IgG presence. These recurrent infections
may also cause cCMV infection [16]. We will therefore refer to
CMV as a non-immunizing infection throughout this manuscript.
Belgium has a total population of about 11 million [17]
divided over the regions of Flanders, Wallonia and Brussels. An
HAV seroprevalence of 55.1% (95% confidence interval (CI)
53.5–56.7%) was reported in 1993 in Flanders [18]. In 2013, a
CMV seroprevalence in women of childbearing age of 41%
(95% uncertainty interval (UI) 28–55%) and a cCMV birth preva-
lence of 52 per 10 000 live births (95% UI 41–64) was estimated in
Belgium [19]. However, these authors also observed that no
age-stratified seroprevalence reports were available at that time,
that the coverage of the studies over Belgium was uneven, and
that these studies showed differences in overall seroprevalence.
Information regarding the epidemiology and burden of infec-
tions is vital for evidence-based health policy. In this context, the
goal of this study was to estimate the age-specific seroprevalence
of CMV infection in Belgium based on two cross-sectional sero-
logical datasets from 2002 and 2006. In order to classify the indi-
viduals as seropositive or seronegative, we used both an approach
based on cut-off values specified by the manufacturers of the diag-
nostic tests and a mixture model approach for the continuous anti-
body levels [20]. Due to its immunizing infection dynamics, the
age-specific seroprevalence of HAV, based on three cross-sectional
serological datasets from 1993, 2002 and 2006, was considered an
excellent comparator for CMV seroprevalence. To better under-
stand further differences between the seroprevalence profiles, we
also estimated and compared the CMV and HAV seroincidence.
Methods
Study population and serological diagnostics
CMV cross-sectional samples were collected in 2002 and 2006,
and examined for the presence of IgG antibodies using two differ-
ent tests. Similarly, for HAV this was done in 1993, 2002 and
2006, and analysed for total (in 1993 and 2002) or IgG antibodies
(in 2006) with three different diagnostic tests. The first set of
samples was collected in Belgian hospitals in the context of base-
line HAV, hepatitis B virus and hepatitis C virus prevalence assess-
ment, cryopreserved and tested for HAV by Sciensano, the Belgian
institute for health [18]. The second set was collected in 2002 in the
context of the European Sero-Epidemiology Network (ESEN2)
project in November 2001–February 2003, and samples were stored
at −80 °C and analysed with the Enzygnost Anti CMV/IgG assay
(Dade Behring, Germany) and the ETI-AB-HAVK PLUS
(DiaSorin, Italy) test for HAV at Sciensano in 2009 [21]. The
third set of samples was collected in January 2006–October 2007
to assess seroprevalence of vaccine-preventable diseases in
Belgium, stored at −40 °C and analysed in 2013 with the CMV
IgG assay for Elecsys and cobas e analysers (Cobas) and the
anti-HAV IgG assay for Elecsys and cobas e analysers at the
Laboratory for Medical Microbiology at the University Hospital
of Antwerp [22]. Serum samples in 2002 and 2006 were collected
from residual blood samples taken at a hospital visit or stay for
individuals under 20 years of age or from donated blood for indi-
viduals of or over 20 years of age. Testing for CMV and HAV fol-
lowed testing of among others measles, mumps, rubella,
varicella-zoster virus (2002) and parvovirus B19 (2002). The major-
ity of samples collected in 2002 and 2006 were tested for both CMV
and HAV, but in some samples, there was not enough serum left to
test both. Antibody levels were expressed in titres according to the
manufacturers’ instructions. Data for HAV represent both natural
and vaccine-induced antibodies because the serological tests used
cannot distinguish between both. No information was available
regarding vaccine uptake. The protocols for the 1993, 2002 and
2006 sero-surveys were approved by the ethical review board of
the University of Antwerp and the University Hospital of Antwerp.
Statistical analysis
We used the cross-sectional serological data to estimate the age-
specific seroprevalence, denoted by π (a). Since maternal anti-
bodies can persist for a few months after birth, we excluded
serological data obtained for children aged <1 year. The fixed
diagnostic cut-off value provided by the producer of the assay
was used to divide a single population in seronegative (δi = 0; sus-
ceptible) and seropositive (δi = 1; infected/recovered) individuals
(with humoral immunity exceeding the threshold, implying past
infection or vaccination). Hence, the immunological status of the
individual, say Δi, conditional on the individual’s age ai follows a
Bernoulli distribution, i.e. Di | ai  B (1,p(ai)). Seroprevalence
by age and birth cohort was estimated for the different study
years using flexible spline models; more specifically thin plate
regression splines [23, 24]. A weighted mean over age was used to
compare the mean overall seroprevalence and subsequent 95% CI
over the different methods and years. A few (0.65%) equivocal
results in the CMV 2006 data were excluded from the analysis.
Alternatively, it is possible to model the observed continuous
antibody levels directly without the specification of (subjective)
cut-off values, thereby avoiding misclassification of individuals
as seropositive or seronegative. In order to do so, one can use
mixture modelling [20, 25]. We used a mixture model with two
mixture components where the log-transformed antibody con-
centration Yi, i = 1, …, n, for the ith subject in the sample condi-
tional on his/her age ai has distribution given by:






2 G. S. A. Smit et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268819000487
Downloaded from https://www.cambridge.org/core. KCE - Belgian Health Care Knowledge Centre, on 18 Mar 2019 at 12:15:27, subject to the Cambridge Core terms of use, available at
The probabilities (1− π (ai)) and π (ai) are the age-dependent
mixture probabilities, for which π (ai) can be interpreted as
the seroprevalence at age ai (4-year age groups). Furthermore,
μj(ai) and s2j (ai), j = 1, 2, are the mean and the variance of log-
transformed antibody concentrations in the susceptible ( j = 1)
and infected ( j = 2) components at age (ai) (4-year age groups)
[20]. Label switching was prevented by using a shift parameter
for the means. We used the maximum likelihood estimation
approach and hence calculated the relevant log-likelihood and
then minimised the negative log-likelihood with general-purpose
optimisation in R version 3.4.2 [26] to estimate the model para-
meters. The likelihood was adjusted to account for left- and right-
censored data. Latin hypercube sampling was used to find a suit-
able set of starting parameters. The goodness-of-fit was evaluated
by visual inspection, including of the density functions. The uni-
variate delta method was used to calculate the variance of the sero-
prevalence and subsequent 95% CI [27]. A weighted mean over the
age groups was used to compare the overall seroprevalence and
subsequent 95% CI over the different methods and years.
The effect of time was assessed by calculating the estimated ser-
oincidence by subtracting the estimated seroprevalence in 2002
(1993) from the seroprevalence in 2006 (2002) in all birth cohorts.
The multivariate delta method was used to calculate the variance
of the seroincidence and subsequent 95% CI. The overall and
age group-specific effect of gender on seroprevalence was assessed
by comparing males and females while using the multivariate delta
method to calculate the variance and subsequent 95% CI [27].
Since diagnostic assays differed between 2002 and 2006, a ran-
dom subset of the 2002 samples was re-tested with the diagnostic
assay used for the 2006 samples. This allowed us to investigate the
influence of using these different assays. We assessed the possibil-
ity of transforming the CMV 2002 quantitative data to match the
2006 data using the censored regression model censReg in R with
exclusion of the censored susceptible component. The seropreva-
lence and seroincidence using the transformed 2002 data were cal-
culated using the mixture model in the same manner as described
above. Furthermore, we assessed if an association could be found
between HAV and CMV antibody titres in both 2002 and 2006
using scatterplots.
Statistical uncertainty about the seroprevalence and seroinci-
dence was quantified as mentioned above and summarised by
the mean and 95% CI and all calculations were performed
using R version 3.4.2 [26].
Results
Cytomegalovirus
In total, 2915 and 1683 serological samples were analysed for
CMV-specific IgG, in 2002 and 2006, respectively, which included
1492 and 837 samples from females and 1423 and 846 from
males, respectively. In 2002, 1943 samples were left-censored
with a titre of 50 as lower limit on the original scale. In 2006,
1088 samples were left-censored at 0.15 U/ml and 142 samples
right-censored at 500 U/ml on the original scale. The mean age
of the population sample was 26 years (95% CI 2.0–64; range
1–72) in 2002 and 29 years (95% CI 2.0–62; range 1–65) in
2006. We did not observe large differences when we transformed
the 2002 data to match the 2006 data, indicating negligible influ-
ence of the diagnostic test differences.
The age group weighted overall CMV seroprevalence estimated by
the mixture model was 32% (95% CI 31–34%) in 2002 and 31%
(95% CI 30–32%) in 2006. A similar age-weighted overall seropreva-
lence was estimated using the spline fit (33%; 95% CI 32–34% in
2002 and 2006). Figure 1 shows the spline fits of the CMV seropreva-
lence in function of age in 2002 and 2006 using the fixed cut-offs (left
panel) and graphically depicts the seroprevalence per age group esti-
mated by the mixture model (right panel). At one year of age the
spline fit showed a seroprevalence of 24% (95% CI 16–32%) in
2002 and 37% (95% CI 28–46%) in 2006. A decrease in seropreva-
lence was observed around the age range 12–23 years in 2002 fol-
lowed by a slow increase reaching 50% around the age of 56 years.
In 2006, a similar but less pronounced decrease followed by a similar
increase reaching 50% around the age of 60 years was seen. Figure 2
shows the seroprevalence of CMV per birth cohort in the total popu-
lation (left column), women (middle column) and men (right col-
umn), separately. The figure depicts the spline fits of the CMV
seroprevalence in function of birth cohorts by using the fixed cut-offs
(upper row) and by the mixture model (lower row).
Figure 3 shows the estimated seroincidence per birth cohort for
the total population (left panels), females (middle panels) and
males (right panels). We compared the 2002 seroprevalence with
that of 2006 per birth cohort, first using the fixed cut-off approach
(upper row). The seroincidence increased in people born after
1999, decreased in people born in the period 1985–1992 and
increased in people born in 1969–1977. There were gender-related
differences. Females born after 1999 showed no increase in seroin-
cidence (whereas males did). Seroincidence decreased in females
born 1985–1991, and increased in females born 1970–1979 and
1949–1955. The mixture model approach (lower row) showed
only a significantly increased seroincidence in males born in
1999–2002, despite it displaying overall similar patterns (including
decreased seroincidence in females born 1987–1994).
For women of childbearing age (16–47 years of age) we esti-
mated an age group weighted seroprevalence of 30% (95% CI
29–30%) in 2002 and 31% (95% CI 30–31%) in 2006. A signifi-
cantly higher seroprevalence was found in women compared
with men in the age groups 16–19 and 36–39 years of age in
2002. In 2006, a significantly higher seroprevalence was found
in women compared with men in general. A significantly lower
seroprevalence was found in women compared with men in the
age group 4–7 years of age and a significantly higher seropreva-
lence was found in the age groups 36–39 and 64+ years in
2006. The age-specific CMV seroprevalence per region at the dif-
ferent time points can be found in Supplementary Figure S2.
Hepatitis A virus
In 1993, 2002 and 2006, respectively, 3792, 3350 and 1620 samples
were tested for HAV antibodies. These samples consisted of 1780,
1689 and 811 samples from females and 2012, 1661 and 809 sam-
ples from males in 1993, 2002 and 2006, respectively. The mean age
in the sampling populations was 40 years (95% CI 5.0–81; range 1–
100) in 1993, 23 years (95% CI 2.0–64; range 1–72) in 2002 and 30
years (95% CI 2.0–63; range 1–65) in 2006. In 2002, 2906 samples
(95.6% of CMV samples and 86.7% of HAV samples), and in 2006,
1609 samples (99.7% of CMV samples and 99.3% of HAV samples)
were tested for both CMV and HAV. We did not observe an associ-
ation between HAV and CMV antibody titres in both 2002 and 2006
(Supplementary Figure S1). Unfortunately, we were not able to use
a mixture model to estimate the seroprevalence of HAV due to
excessive censoring of the continuous antibody titre levels.
The age-weighted overall HAV seroprevalence using the spline fit
was 54% (95% CI 38–70%) in 1993, 26% (95% CI 18–33%) in 2002
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and 31% (95% CI 23–39%) in 2006 in Belgium. Figure 4 shows
that the estimated HAV seroprevalence increases with age, with
low seroprevalence in young and middle-aged adults and high
seroprevalence in the elderly. In 1993, the seroprevalence reached
50% in people around 35 years of age, whereas in 2002 and 2006,
50% seroprevalence was only reached around the age of 45 years.
Fig. 1. Cytomegalovirus seroprevalence in function of age in 2002 and 2006 estimated by using splines and fixed cut-offs and by the mixture model.
Note: Age groups consist of 1 year in the spline fit and 4 years in the mixture model.
Fig. 2. Cytomegalovirus seroprevalence by birth cohort in 2002 and 2006 estimated by splines and fixed cut-offs and by the mixture models (rows) for the total
population, females and males (columns). Note: Birth cohorts consist of 1 year in the spline fit and 4 years with in the mixture model.
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Figure 5 shows the seroincidence per birth cohort for 2002
compared with 1993 (left panel), 2006 compared with 1993 (mid-
dle panel) and 2006 compared with 2002 (right panel). It shows
that persons born before 1976 did not gain any noticeable
immunity against HAV between 1993 and 2002 and persons
born before 1964 between 1993 and 2006. In contrast, younger
persons have, on average, gained non-negligible immunity, either
through natural infection or through vaccination. A negative
Fig. 3. Cytomegalovirus seroincidence by birth cohort in 2006 compared with 2002 estimated using splines and fixed cut-offs and by the mixture models (rows) for
the total population, males and females (columns). Note: Birth cohorts consist of 1 year in the spline fit and 4 years in the mixture model.
Fig. 4. Seroprevalence of hepatitis A virus antibodies as a function of age and birth cohorts in 1993, 2002 and 2006 resulting from primary infection or vaccination
using splines and the fixed cut-offs.
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seroincidence could be observed when we compared the 2002 and
2006 data from people born after 1996, whereas people born
1959–1989 gained non-negligible immunity. The age-specific
HAV seroprevalence per region at the different time points can
be found in Supplementary Figure S3.
Discussion
The seroprevalence of CMV infection was estimated either by using
a fixed cut-off approach or by considering a mixture model for
continuous antibody titre concentrations. In addition, CMV infec-
tion dynamics were assessed by studying serial serology of CMV
and HAV. Unfortunately, we were unable to estimate the seropreva-
lence and seroincidence of HAV with a mixture model due to
excessive censoring. This is unfortunate especially since it has
been shown that the antibody response to natural infection is stron-
ger than to vaccination. Vaccine-induced antibody levels might
wane over time, which makes setting appropriate cut-off values
for diagnostic tests difficult [28]. The main advantages of using a
mixture model are that all information is used on the original
(or transformed) continuous scale of antibody activity levels and
that observations are assumed to originate from two (or more) dis-
tributions, referring to a susceptible and an infected subpopulation
(among other possible subpopulations), with different distribu-
tional parameters. This implies that the somewhat subjective cut-
offs provided by the manufacturer, usually chosen on clinical diag-
nostic or screening grounds, do not have to be used. Next to the
difficulties encountered with setting meaningful cut-off values to
continuous distributions, the choice of cut-offs also depends on
the aim of the test. From an epidemiological perspective, the sero-
prevalence in the population at each age, not the detection of clin-
ical significant antibody levels in an individual, is the primary
consideration, which makes the mixture model a more appropriate
method [20, 29, 30].
The age group-weighted overall CMV seroprevalence estimated
by the mixture model was found to be 32% (95% CI 31–34%) in
2002 and 31% (95% CI 30–32%) in 2006. This is low compared
with seroprevalances found in other countries and in Belgium.
The systematic review and random-effects meta-regression by
Zuhair et al. [2] estimated a mean seroprevalence in the general
population of 83% (95% UI 78–88%) globally, with the lowest in
the European region (66% (95% UI 56–74%)) and Ireland (39%
(95% UI 18–62%)) in contrast to the highest in the Eastern
Mediterranean region (90% (95% UI 85–94%)) and Turkey (96%
(95% UI 93–98%)). For women of childbearing age (16–47 years
of age), we estimated an age group-weighted seroprevalence of
30% (95% CI 29–30%) in 2002 and 31% (95% CI 30–31%) in
2006, which is lower compared with the meta-analysis-based esti-
mate for Belgium of 41% (95% UI 28–55%) by Smit et al. [19].
Whilst seroprevalence estimates in the mixture model closely
reflected those using the fixed cut-off approach, the main difference
between the two methods was found in the peaks observed in the
age group 40–43 years for both 2002 and 2006 in the mixture
model. Both methods showed that a sizable fraction was infected
before one year of age and that the CMV seroprevalence in 2002
and 2006 showed a ‘dip’ in the age range 12–39 years followed
by a slow increase reaching 50% around the age of 56 years in
2002 and 60 years in 2006. The decrease in seroprevalence might
be explained by the sampling method, which included two groups:
individuals under 20 years who visited the hospital for diagnosis or
screening and blood donors of and over 20 years of age. This seems
plausible since the HAV data in 2002 and 2006 had a similar sam-
pling scheme and showed a similar ‘dip’ between approximately 20
and 35 years of age, in contrast to the HAV data from 1993, which
were based on hospital samples. These two groups, hospital
patients and blood donors, might differ in health status, since
blood donors are screened for some infectious diseases and
excluded when found at risk or positive. Other factors might be
of influence as well, such as socio-economic status, with lower levels
being associated with higher seroprevalence [31].
The spline fit and the mixture model showed an increased ser-
oincidence in males born before 1999 (2 years of age in 2002 and
6 in 2006) and additionally in the total population with the fixed
cut-off approach. Interestingly, both methods (although not sig-
nificant in the mixture model) showed a decreased seroincidence
in females and the total population born approximately between
1985 and 1991 (11–17 years of age in 2002 and 15–21 in 2006).
We cannot fully link this phenomenon to the sampling method
(samples from individuals visiting the hospital under 20 years
and from blood donors of and over 20 years of age), since if
this were the case we would suspect the negative seroincidence
to be present in the birth years 1983–1986 (16–19 years of age
in 2002 and 20–23 in 2006). Next to the possibility of an artefact
or confounding factors, this might also indicate a violation of the
assumptions of lifelong immunity; time equilibrium at the disease
and/or population level; or that mortality attributable to CMV
Fig. 5. Seroincidence of hepatitis A virus antibodies per birth cohort comparing 2002–1993, 2006–1993 and 2006–2002 estimated using splines and the fixed
cut-offs.
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infection can be ignored. A similar dip in the seroprevalence fit at
a similar age was shown by Goeyvaerts et al. [12] for human
parvovirus B19, which made them question and explore the
assumption of lifelong immunity. We cannot rule out a cohort
effect due to a demographical shift or CMV related mortality.
However, it has been shown that the virus can reactivate and
reinfection with a different CMV strain can occur [16]. This
may imply that the assumption of primary infection followed
by lifelong immunity, including IgG-positive antibody levels,
might not hold and that boosting through reactivation and
reinfection is likely.
Gaining insight in the processes underlying CMV infection
dynamics is of major public health interest especially since an
increase in IgG seroprevalence between 2002 and 2006 was
observed in the child-bearing age category of the total population
and females specifically. The risk in pregnant women might then
be underestimated. This increased seroincidence was seen in the
spline fit in females and the total population born between
approximately 1970 and 1977 (25–32 years of age in 2002 and
29–36 in 2006) and in females born between 1949 and 1955
(48–52 years of age in 2002 and 52–56 in 2006). Furthermore,
we noticed a higher seroprevalence in women compared with
men between 36 and 39 years of age, which might indicate a faster
increase in seroprevalence in recent mothers (having young chil-
dren in the household).
Although not directly comparable, a similar difference between
men and women was seen in the NHANES study in the USA [32].
In the Netherlands, van Boven et al. [15] merged a statistical ana-
lysis with transmission models and described three distributions of
antibody measurements: low, intermediate and high antibody con-
centrations, which were related to the uninfected, latently infected
and latently infected after reactivation or reinfection groups,
respectively. In contrast to other infectious diseases, e.g. as seen
for HAV [33], the Dutch CMV seroprevalence increased gradually
with age. Their findings indicated that the transmissibility of pri-
mary infection is much lower than the transmissibility after reacti-
vation and add to the belief that transmission from adults after
infectious reactivation is an important driver of CMV transmis-
sion in the population. Noteworthy is that they found a higher
incidence of infection in adult women than in adult men of similar
age [15]. However, the possibility of antibody waning has not been
observed nor tested yet. The majority of studies show a gradual
increase in seroprevalence with age [31] although there seem to
be studies that might have similar seroprevalence patterns com-
pared with our data (see, e.g. Barbi et al. [34]; de Ory et al.
[35]; Wentworth et al. [36]). We cannot directly compare the
methodology and results of the studies described above with our
study, yet our data at least show that CMV infection dynamics
do not follow the same pattern as we observe for HAV.
Similarly to what has been reported by Beutels et al. [18] and
Kurkela et al. [7], HAV antibody presence increased with age,
with low seroprevalence in young and middle-aged adults and
high seroprevalence in the elderly, indicative of historic transmis-
sion. The HAV seroprofile in birth cohorts to some extent appears
to reflect that endemic circulation seemed to be discontinued
around the 1970s, potentially due to changes in hygienic and
socio-economic conditions over time [7, 33].
An increased seroincidence was observed in the birth cohorts
born after 1976 in 2002 (26 years of age in 2002), as already noted
by Beutels et al. [33], and 1964 in 2006 (42 years of age in 2006)
compared with the set of samples in 1993. People born between
1959 and 1989 (17–47 years of age in 2006) gained non-negligible
immunity when we compared the 2002 and 2006 datasets. This
might be explained, at least partly, by outbreaks [37] and by vac-
cination of high-risk groups (including, e.g. health care workers,
travellers to endemic regions and people with haemophilia) and
by the fact that vaccination was used as outbreak control measure
[7] from 1992 onwards in Belgium. It was estimated that 708 095
people between 1995 and 2006 (or 6.7% of all Belgian residents)
received a full HAV vaccine schedule in Belgium [33]. In contrast,
a negative seroincidence could be observed when we compared
the 2002 and 2006 data from people born after 1996 (10 years
of age in 2006). This might be explained by the detection of
total antibodies in 2002 in contrast to IgG antibodies in 2006.
The high susceptibility to HAV in young and middle-aged adults
demonstrates that it might be beneficial to continue vaccination of
risk groups in Belgium. Children between 1 and 12 years of age
travelling to high endemic regions were recommended for tar-
geted vaccination by Beutels et al. [33], since these children can
be an important source for outbreaks when they return with
asymptomatic HAV infection in a society with increasing propor-
tions of susceptible adults.
The strengths of this study were the availability of serial sero-
logical data with age specification; the possibility of comparison
between the CMV infection dynamics and the immunizing HAV
infection dynamics; and the use of a mixture model. The limita-
tions, however, were the censoring in the serological data; and
the comparability between the different datasets and thus popula-
tions, based on the sampling scheme and the diagnostic methods
used (e.g. the majority of samples from individuals under 20 years
of age especially in 2002; datasets containing hospital samples of
individuals under 20 years and samples of blood donors of and
over 20 years of age in 2002 and 2006 and only hospital samples
(mainly from Flanders) in 1993; different diagnostic assays used;
and detection of total HAV antibodies in 1993 and 2002 in con-
trast to only HAV IgG in 2006). This study reinforces the import-
ance of distinguishing between sampling sources.
We acknowledge that CMV and HAV are different viruses, yet
our aim was to compare the seroprevalence profile over age of
CMV with an infection known to confer lifelong immunity,
implying in theory a monotonically increasing seroprevalence
pattern over lifetime, which may not necessarily be observed in
a cross-sectional population sample by age. In a potential com-
parison of CMV with measles, mumps or rubella, vaccination
for the latter pathogens would play too much of a role. HAV vac-
cination was limited to approximately 7% of all Belgian residents
[33], which is likely to be similar to the percentage for this dataset.
Moreover, seroprevalence of both HAV and CMV is known to be
related to socio-economic status [6, 7, 31, 33] indicating similar-
ities in transmission.
We showed that the CMV infection dynamics do not follow
the same patterns as those for HAV infections. To be able to
explain the observed seroprevalence profile, a prospective cohort
study and/or several serial studies are needed. The latter option
should be population-based or at least include a head-to-head
comparison to reveal the bias (e.g. hospital patient–age–year vs.
blood donor–age–year). In the absence of such data, it might be
beneficial to explore several immunological scenarios in mathem-
atical models and infer waning and boosting rates using sero-
logical and social contact data. Similar studies were performed
for human parvovirus B19 [12], measles [38], pertussis [39, 40]
and CMV as described previously [15]. It would be of interest
to study the possibility of antibody waning and multiple (re)infec-
tion and reactivation events in the case of CMV infections.
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This was the first large-scale study of CMV and HAV serial
serological survey datasets in Belgium, estimating age and birth
cohort-specific seroprevalence and seroincidence. In addition,
it highlights the benefits of using a mixture model for epidemio-
logical purposes and that it is important to distinguish between
sampling sources. We further demonstrated that the CMV epi-
demiology differs from that of an immunizing infection such as
HAV. Good surveillance systems need to be maintained to moni-
tor continuously changing trends, and to support the implemen-
tation of appropriate intervention and prevention policies.
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